Astrana Health, Inc. (ASTH)
(Delayed Data from NSDQ)
$39.06 USD
-1.84 (-4.50%)
Updated May 20, 2024 04:00 PM ET
After-Market: $39.00 -0.06 (-0.15%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ASTH 39.06 -1.84(-4.50%)
Will ASTH be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ASTH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ASTH
Here is Why Growth Investors Should Buy Astrana Health, Inc. (ASTH) Now
DaVita HealthCare (DVA) Surpasses Q1 Earnings and Revenue Estimates
ASTH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Option Care (OPCH) Q1 Earnings and Revenues Surpass Estimates
Astrana Health Inc. (ASTH) Q4 Earnings and Revenues Top Estimates
Other News for ASTH
Astrana Health Shares Financial Overview with Investors
Astrana Health, Inc. to Participate in Upcoming Investor Conference
Stifel Nicolaus Reaffirms Their Buy Rating on Astrana Health (ASTH)
Lake Street Remains a Buy on Astrana Health (ASTH)
Astrana Health, Inc. Reports First Quarter 2024 Results